The molecular basis of most @thalassemia syndromes has been defined, while the spectrum of mutations causing 8-thalassemia is not well characterized. In an attempt to identify such mutations, the region encompassing the 8-globin gene from three Greek Cypriot families suspected of having &thalassemia was amplified by polymerase chain reaction (PCR), and DNA sequence determined using an automated fluorescence-based sequencer. Four novel mutations were identified: a G + T change at codon 27 that results in an alanine to serine change; a C + T change at codon 116 converting arginine to cysteine; a T -+ C change at codon 141 converting leucine to proline; and an AG + GG change at the HE &GLOBIN CHAIN is the P-like subunit of hemo-
consensus 3'-acceptor site in IVS-2. While the latter is clearly a thalassemic mutation, the low hemoglobin A, in the first three may be due to either decreased production or instability of the altered 8-globin chain. All four mutations may be detected by PCR amplification of genomic DNA followed by restriction enzyme digestion. Two mutations abolish restriction sites while two create new cleavage sites. Screening for molecular defects that cause &thalassemia or unstable 6-globin by PCR amplification and restriction enzyme digestion will lead to correct diagnosis of p/a-thalassemia compound heterozygotes and improved genetic counseling. 0 1991 by The American Society of Hematology.
the 5'-donor splice site of IVS-1 that abolishes the splice donor site and leads to complete absence of &globin messenger RNA (mRNA).' Another mutation from southern Italy, a G --$ C change at codon 30, interferes with normal &globin mRNA splicing of IVS-l.R A G'-thalassemia gene from a Sardinian family had a G -+ T change at codon 27 (ala -+ ser) that presumably also activates a cryptic splice site resulting in aberrant transcript processing.' There is also a report of a 6'-thalassemia gene in an African-American due to a G -+ T change at codon 98 (Val -+ met) that is thought to lead to instability of the variant Hb
Recently, a G A substitution 69 bp downstream of the poly A addition site of the &globin gene was reported in a patient with G+-thalassemia; however, it is not clear whether this is the disease-causing mutation or a neutral sequence polymorphism.* Additional cases of &thalassemia have been reported, but without complete molecular studies.","
In this report, we have characterized four different &globin gene mutations in three unrelated Greek Cypriot families suspected of having &thalassemia. We have also implemented a polymerase chain reaction (PCR)-based strategy for identifying these mutations that should facilitate rapid screening for %thalassemia in this population.
MATERIALS AND METHODS
Hematologic data, DNA extraction, and a-globin gene analysis. Hematologic studies, DNA isolation, and Hb A2 determinations were performed in Cyprus, using standard protocol^,'^^'^ while Southern blots were performed at the Children's Hospital of Philadelphia, as previously described.14 The a-globin gene analysis included gene blotting after digestion of genomic DNA with BamHI and BglII, and subsequent hybridization with an a-gene cDNA probe.I5
Oligonucleotide primers. Oligonucleotide primers were prepared using phosphoramidite chemistry on a 380B DNA synthesizer (Applied Biosystems, Inc, Foster City, CA). Primers 1 to 8 were synthesized with the trityl group off; while primers 9 to 14 were synthesized with the trityl group on, and were subsequently purified on OPC columns (Applied Biosystems). Primer 15 was supplied with the Taq Dye Primer Cycle Sequencing Core kit (Applied Biosystems). The primers used are listed in Table 1 .
Amplification of &globin gene and fluorescent DNA sequence analysis using cycle sequencing. Portions of the &globin gene were (Perkin-Elmer Cetus, Norwalk, CT) was added. Samples were covered with 100 pL of paraffin oil and incubated in a DNA thermal cycler (Perkin-Elmer Cetus) at 96°C for 30 seconds, 55°C for 1 minute, and 72°C for 1 minute for a total of 30 cycles. Samples were then extracted with 100 pL of chloroform, and 10 pL was electrophoresed on a 1.8% (wt/vol) agarose gel to monitor the size of the PCR products. A second round amplification for each of the initial four reactions included 1 pL of the first PCR product as template (Fig 1C) . Reactions were as described above except that 1.6 pL of dNTPs was used, 1.5 pmol of a different 5'-limiting primer, and 50 pmol of the same 3' primer as in the initial PCR were used. The 5'-limiting primer used in the second amplification is a nested primer to which the M13 universal primer sequence has been attached (primers 9 through 14 in Table 1 ). This serves to incorporate the M13 universal primer into the second round PCR products, enabling the complementary strand to serve as template for DNA sequence analysis using dye-tagged M13 universal primer added later. The 5'-nested primers used in the second amplifications were as follows: primer 9 for amplification of (113) PCR products; primers 10 and 11 for (2/6) products; primer 12 for (417) products; and primers 13 and 14 for (5/8) first round PCR products. Second round amplification cycles (denaturation/ annealing/extension) were at 96°C for 30 seconds, 50°C for 1 minute, and 72°C for 2 minutes with each additional cycle increased by a 5-second polymerase extension for a total of 20 cycles. After the second PCR, the products were extracted and subjected to electrophoresis, as described above. The products of the second PCR were used as template for fluorescence-based DNA sequence analysis with Taq polymerase using the Taq Dye Primer Cycle Sequencing Core kit supplied by Applied Biosystems. Four reactions were run per sample, each corresponding to terminations with one of the four ddNTPs. One microliter of template was mixed with 1 pL of appropriate d/ddNTP mix, 1 pL of 5X cycle sequencing buffer, 1 pL of Taq polymerase (0.6 U), and 1 pL of the appropriate dye primer (0.4 pmol/p,L) for the A and C terminations. Volumes were doubled for G and T terminations. Each of the four reactions were overlaid with 20 pL of paraffin oil, and placed in a thermal cycler preheated to 95°C. Thermal cycling was performed at 95°C for 30 seconds, 55°C for 30 seconds, and 70°C for 1 minute for 15 cycles, followed by another 15 cycles at 95°C for 30 seconds and 70°C for 1 minute. The four reactions were then extracted from underneath the oil and pooled. Fluorescent-tagged extension products were precipitated by addition of 80 pL of 95% ethanol and 1.5 pL of 3 mol/L NaOAc, pH 5. The sequence obtained from each run was compared with the known sequence of the &globin gene" with the help of SeqEd, a software program (Applied Biosystems).
PCR-based identijication of mutations after restriction enzyme digestion. Digests contained 20 U of a restriction enzyme (EcoO 109 I, Suu96 I, Hpa 11, or Sac II), 15 pL of a first round PCR product, and buffer conditions as described by the manufacturer (Bethesda Research Laboratories, Gaithersburg, MD, or New England Biolabs, Beverly, MA). Digests were incubated at 37°C overnight, and then subjected to electrophoresis on a 1.8% (wtivol) agarose gel in 1X TBE buffer (89 mmol/L Tris-borate, 89 mmol/L boric acid, and 2 mmol/L EDTA) containing ethidium bromide. Bands were visualized by transillumination with a UV light source (Hoefer Scientific Instruments, San Francisco, CA).
Sequence alignment and comparison.

RESULTS
Hematologic data from the three Cypriot families studied are summarized in Table 2 . Family A consists of an extended pedigree of 25 individuals, seven of whom are listed in Table 2 . Individual 11-3 of family A has no detectable Hb A,, suggesting the presence of homozygous &thalassemia. Blotting studies for a-genes showed an a3.'/aa genotype in 11-3 (data not shown). Her husband (11-4) is a classic @-thalassemia carrier with high Hb A, (4.5%) and a low mean corpuscular volume (MCV) (69.6). Their son (111-2) is suspected of inheriting a &thalassemia gene from his mother (11-3) and a P-thalassemia gene from his father . Inheritance of the maternal &thalassemia gene masks proper diagnosis of @-thalassemia because this individual has a normal Hb A, level (2.5%) with a low MCV (66.0). Individual 111-1 is a suspected compound heterozygote for 6-thalassemia, inheriting an Hb A,-electrophoretic variant with decreased production from his mother (11-1) and a &thalassemia gene from his father . This electrophoretic variant migrates between Hb S and Hb F on cellulose acetate, pH 8.9. In family B, 11-3 has a low Hb A, (0.2%) and is presumed to be homozygous for S-thalassemia. All other members of this family, with the exception of 11-1, were suspected 6-thalassemia heterozygotes due to their low Hb A, levels (1.5% to 1.7%).
In family C, 11-1 has no detectable Hb A,, suggesting homozygosity for &thalassemia. Two of her sisters (11-2 and 11-4), as well as her parents (1-1 and 11-2), have decreased Hb A2 levels (1.4% to 1.6%), consistent with heterozygosity for &thalassemia.
&Globin genes from patients suspected of having a &thalassemia syndrome (eg, 11-3 and 111-1 in family A, 11-3 in family B, and 11-1 in family C) were amplified using PCR and DNA sequence determined from -220 nucleotides 5' to the cap site to +50 nucleotides 3' to the poly A signal site. DNA sequence at nucleotides -159 and -146 5' to the cap site was not determined due to technical problems leading to sequence stops at these positions that were observed in all samples, suggesting that they represent a sequence artifact. The cycle sequencing strategy16 used for fluorescence-based DNA sequence analysis is outlined in Fig 1. This strategy incorporates the M13 universal primer sequence into the second round-seminested PCR product for subsequent use as a template using a dye-tagged M13 universal primer with fluorescence-based DNA sequence analysis (Fig 1E) .
Portions of the sequence printouts in which mutations were found are shown in Fig 2. Individual 11-3 from family A, who has no detectable Hb A,, is homozygous for a T -+ C change at the second position of codon 141 that, if expressed, would result in a leucine to proline substitution (Fig 2C) . Individual 111-1 from family A, who expresses low levels of an Hb A, variant (0.6%), is a compound heterozygote for S-thalassemia containing two different 6-globin gene mutations. In addition to the same T -+ C change at codon 141 in one of his 6-globin genes, a C --$ T change was found in the other gene at the first position of codon 116 that converts arginine to cysteine (Fig 2B) . Individual 11-3 from family B, who expresses low levels of Hb A, (0.2%), is also a compound heterozygote for &thalassemia. He has a G -+ T change at the first position of codon 27 that converts alanine to serine in one 6-gene (Fig 2A) ; in addition, he has an A -+ G change in his other 6-gene at the 3'-splice acceptor site of IVS-2 (Fig 2D) . This individual is also homozygous for a C -+ T change at position -199 nucleotide 5' to the cap site of the 6-globin gene (sequence printout not shown) that is most likely a neutral sequence . . . . 3"S2 I LEU . . . For personal use only. on October 30, 2017. by guest www.bloodjournal.org From 3302 TRlFlLLiS ET AL polymorphism. Individual 11-1 from family C is homozygous for both the -199 polymorphism and for an A -G change at the 3'-splicc acceptor sitc of IVS-2 ( Fig 2D) .
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Four of the five observed changes within the &globin gene result in either the generation or loss of a restriction endonuclease cleavage site that is readily detected on sizing gels after digestion of the appropriate PCR products. The G -+ T change at codon 27 (ala --* ser) and the C -T change at codon 116 (arg -cys) abolish EcoO 109 I (AG'GCCCT-AGTCCCT) and Suu96 I (G'GCCC -GGCCT) sites, respectively; while the T + C change at codon 147 (leu-pro) and the AG -GG change at the 3'-acceptor site of 1%-2 create Hpu I1
(CTGG -C'CGG) and Sac 11 (CCGC-G -CCGC'SG) sites, respectively. EcoO 109 I was used for digestion of first round PCR products using primers 1 and 6; Suu96 I, Hpu 11, and Sac I1 were used for digestion of first round PCR products using primers 5 and 8 (see Table 1 ). Representative digest patterns of PCR products are shown in Fig 3 . Fig 3C) ; while the A -+ G mutation in the 3'-acceptor site of IVS-2 generates a new Sac I1 site resulting in digestion of the normal 947-bp band into 632-and 315-bp bands (Fig 3D) . Inheritance patterns for the various &globin gene mutations and relevant hematologic data for the three Cypriot families are summarized in heterozygotes for the 6 141 (leu -+ p r o ) change and a p-thalassemia allele resulting in 2.1% and 2.5% Hb A, (eg, 111-2). In a branch of this family a 6 116 (arg + cys) variant is seen, so two individuals are compound heterozygotes for the 6 141 (leu --+ pro) change and 6 116 (arg + cys) variant with 0.5% and 0.6% Hb A, variant and no Hb A, (eg, 111-l), and one is a heterozygote for the 6 116 (arg + cys) variant expressing 1.4% Hb A, and 0.5% Hb A, variant (eg, 11-1). Nine individuals in this family are normal and two are deceased. In family B, three individuals are heterozygotes for the A -+ G mutation in the 3'-acceptor site of IVS-2 and express 1.5% to 1.7% Hb A,, one is a heterozygote for the 6 27 (ala --* ser) variant with 1.7% Hb A,, one is a heterozygote for the 6 27 (ala+ ser) variant and the A + G mutation in the 3'-acceptor site of IVS-2, with 0.2% Hb A,, and one is normal. In family C, four individuals are heterozygotes for the A + G mutation in the 3'-acceptor site of IVS-2 with 1.4% to 1.6% Hb A,, one is a homozygote for this mutation with no detectable Hb A,, and one is normal. Because homozygosity for the splice defect results in no Hb A, (family C, 11-1), the 0.2% Hb A, detected in individual 11-3 of family B probably represents expression from the 6 27 (ala -+ ser) gene.
DISCUSSION
In this study we describe the characterization of four novel mutations causing &thalassemia or unstable &globin variants in Greek Cypriots. One structural variant (6 141 [leu += pro]) leads to absence of &chains while two others (6 27 [ala+ ser] and 6 116 [arg+cys]) cause a 6'-thalassemia phenotype. We propose to name the three variants after the villages in Cyprus where these patients reside: 6 27 (ala + ser), Hb A,-Yialousa; 6 116 (arg + cys), Hb A,-Troodos; and 6 141 (leu +pro), Hb A,-Pelendri. The fourth mutation described here abolishes the 3'-acceptor site in IVS-2 and leads to a 6"-thalassemia phenotype. While this report was in review, the identical &globin 116 variant was described in a Greek family (Hb A,-Corfu).18 In that instance, the relative amount of the variant was not reduced in the simple heterozygote. Hb A, was 1.3% and Hb A,-Corfu 1.5%, while in our family A Hb A, was 1.4% and the variant 0.5% (Fig 4, family A, 11-1 ). The decreased MCV in the Hb A,-Corfu heterozygote (75 fL) is unexplained; in our family A, 11-1, MCV was 93.7 fL (Table   The amino acid change from leucine to proline at codon 141 is a nonconservative substitution. Proline interferes with a-helix formation." Thus far, 24 p-chain variants have been reported that change an amino acid to proline. Twenty-one of these variants result in unstable Hbs." In addition, position 141 in the p-chain of Hb is in the interior of the molecule and its hydrophobic side chain is in direct contact with the heme group." In p-globin, a change to arginine at codon 141 results in marked instability of Hb A tetramers," while an alanine to proline change at p 142 (H20) results in instability and heme loss. 23 The substitution of 8 141 (H19) leu + pro observed here is at a homologous site with the a-chain variant Hb Bibba a 136 (H19) leu + pro, which is also a very unstable ~ariant.'~ From these data and our observation that no Hb A, was detected in two siblings homozygous for this mutation, it appears likely that the change from leucine to proline at this position in &globin results in marked instability of the variant Hb A,.
The 6 The 6 27 (ala + ser) variant was described previously in a Sardinian family.7 No electrophoretic variant is seen after electrophoresis, indicating a lack of change in the charge of the protein. The region in which this mutation occurs is completely homologous between the 6-and the 6-globin genes. The exact G + T change at this position in P-globin produces the Hb variant Hb K~O S S O S ,~~ but also results in a P'-thalassemia phenotype due to aberrant transcript splicing caused by activation of a cryptic donor splice ~i t e .~' Normal splicing leads to the introduction of a serine residue at codon 27 that might render the protein unstable, as seen in the case of Hb Volga p 27 (ala -+ asp)." On the other hand, abnormal splicing leads to an inframe-deletion of codons 27 to 30, which form part of helix B. Amino acid substitutions have been identified in each one of these codons that result in unstable Hb
The 6 27 (ala + ser) mutation reported now in a Greek Cypriot and previously in a Sardinian probably results in a 6'-thalassemia phenotype by causing some degree of abnormal splicing and protein instability.
The A + G change in the 3'-acceptor site of IVS-2 of the &globin gene appears responsible for total absence of Hb A,. The same change in the P-globin gene results in a p-thalassemia phenotype, because no normally spliced transcripts are p r o d u~e d .~~,~~ The 3'-acceptor site in IVS-2 of the p-gene is abolished and a new cryptic acceptor site at position 579 of IVS-2 is used. This alternate splicing produces transcripts in which the IVS-2 is only partially excised. The resulting mRNA cannot encode for p -g l~b i n .~~ The interaction between the 3'-acceptor site mutation and the 6 27 (ala + ser) mutation (family B, suggests that the 6 27 (ala + ser) gene expresses very low levels of Hb A, (0.2%). This finding is consistent with a S'-thalassemia phenotype due to activation of a cryptic donor splice site.
The -199 polymorphism reported here is at a position in the promoter that is important for expression of the y-globin gene. Three mutations at positions -202, -198, and -196 5' to the y-globin cap site have been reported to cause hereditary persistence of fetal Hb.38-40 However, no homology exists in this region between the y-and the &globin gene promoters.
Implementation of our PCR-based strategy for detection of these &globin gene mutations by specific restriction enzyme digestion will now allow rapid identification of individuals with these mutations, and should clarify the status of individuals with normal Hb A2 levels and p-thalassemia trait. While measurements of Hb A, levels in affected individuals and family members may help in making a clinical diagnosis in many instances, the molecular biology techniques described here for specific and rapid diagnosis should be useful for individual diagnosis as well as for population studies. Data from Cyprus indicate that 1.3% of Cypriots screened for p-thalassemia have Hb A, levels between 0.0% and 1.5%, suggesting that the occurrence of &thalassemia or unstable &globin variants in Cyprus is quite high. Characterization of compound heterozygotes for p/G-thalassemia will help improve genetic counseling in the Cypriot population and in other areas where p-thalassemia syndromes are prevalent.
